SciSparc (NASDAQ:SPRC) Upgraded by Wall Street Zen to “Hold” Rating

Wall Street Zen upgraded shares of SciSparc (NASDAQ:SPRC) to a hold rating in a research report report published on Saturday morning.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of SciSparc in a research report on Tuesday, May 26th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has a consensus rating of “Sell”.

SciSparc Stock Down 6.7%

NASDAQ:SPRC opened at $5.00 on Friday. SciSparc has a twelve month low of $2.98 and a twelve month high of $80.10. The business has a 50 day moving average price of $6.51 and a two-hundred day moving average price of $6.55.

SciSparc (NASDAQ:SPRC) last posted its quarterly earnings data on Wednesday, April 29th. The company reported ($31.60) earnings per share (EPS) for the quarter. The firm had revenue of $0.20 million for the quarter.

SciSparc Company Profile

SciSparc AG is a clinical‐stage medical technology company focused on the development and commercialization of extracorporeal shock wave–based neuromodulation devices. Founded in 2016 and headquartered in Switzerland, the company applies proprietary low‐intensity shock wave technology to noninvasively stimulate neural tissue. SciSparc completed its initial public offering on the NASDAQ in 2021 under the ticker SPRC, securing funding to advance its clinical pipeline.

The company’s lead product, the TR100 system, delivers transcranial shock wave stimulation (tSWS) designed to target areas of the brain associated with motor control and cognitive function.